

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
21 September 2023 (21.09.2023)



(10) International Publication Number
WO 2023/178061 A1

(51) International Patent Classification:

C07C 45/63 (2006.01) C07C 62/38 (2006.01)
C07C 49/603 (2006.01) C12P 7/40 (2006.01)
C07C 51/10 (2006.01)

(21) International Application Number:

PCT/US2023/064277

(22) International Filing Date:

14 March 2023 (14.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/269,370 15 March 2022 (15.03.2022) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).

(72) Inventors: **MCKENNA, Shane**; c/o Bristol-Myers Squibb
Company, Reeds Lane, Moreton, Cheshire CH46 1QW
(GB). **TAN, Yichen**; c/o Bristol-Myers Squibb Compa-
ny, Route 206 and Province Line Road, Princeton, New
Jersey 08543 (US). **SMITH, Michael J.**; c/o Bristol-My-
ers Squibb Company, Route 206 and Province Line Road,
Princeton, New Jersey 08543 (US). **FOX, Richard J.**; c/
o Bristol-Myers Squibb Company, Route 206 and Province
Line Road, Princeton, New Jersey 08543 (US). **GEORGE,**
David Thomas; c/o Bristol-Myers Squibb Company, Route
206 and Province Line Road, Princeton, New Jersey 08543
(US). **JOE, Candice Lee**; c/o Bristol-Myers Squibb Com-
pany, Route 206 and Province Line Road, Princeton, New
Jersey 08543 (US).

(74) Agent: **SUN, Jing G.** et al.; Bristol-Myers Squibb Compa-
ny, Route 206 and Province Line Road, Princeton, New Jer-
sey 08543 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

WO 2023/178061 A1

(54) Title: BIOCATALYTIC SYNTHESIS OF (1S,3S)-3-HYDROXYCYCLOHEXANE-1-CARBOXYLIC ACID COMPOUNDS

(57) Abstract: Improved methods and intermediates thereof for preparing (1S,3S)-3-hydroxycyclohexane-1-carboxylic acid are de-
scribed. These compounds are useful as intermediates for making carbamoyloxymethyl triazole cyclohexyl acid LPA antagonists.